Tvardi Therapeutics (NASDAQ:TVRD) Earns Overweight Rating from Analysts at Barclays

Key Points

• Barclays analysts have initiated coverage of Tvardi Therapeutics with an "overweight" rating and a price target of $61.00.
• Tvardi Therapeutics has seen a significant decline, with its shares trading down 83.9% from a twelve-month high of $43.65 to $6.69.
• Despite mixed ratings from multiple analysts, the consensus provides an average rating of "Moderate Buy" with a target price of $55.50.

Investment analysts at Barclays began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) in a research report issued on Monday, Marketbeat reports. The firm set an "overweight" rating and a $61.00 price target on the stock.

A number of other research analysts also recently commented on TVRD. Piper Sandler downgraded shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday. Raymond James Financial started coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They issued an "outperform" rating and a $62.00 target price on the stock. BTIG Research dropped their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday. Weiss Ratings reaffirmed a "sell (e)" rating on shares of Tvardi Therapeutics in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $55.50.

Tvardi Therapeutics Trading Down 83.9%

Shares of TVRD opened at $6.69 on Monday. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65. The firm has a fifty day moving average price of $31.63.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics during the 2nd quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Tvardi Therapeutics during the 2nd quarter worth $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics during the 2nd quarter worth $80,000. New York State Common Retirement Fund acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth $92,000. Finally, Bank of America Corp DE acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth $399,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.